<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04893811</url>
  </required_header>
  <id_info>
    <org_study_id>B1971060</org_study_id>
    <secondary_id>2018-002588-24</secondary_id>
    <nct_id>NCT04893811</nct_id>
  </id_info>
  <brief_title>Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age</brief_title>
  <official_title>A PHASE 4, OPEN-LABEL, SINGLE-ARM TRIAL TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF TRUMENBA(REGISTERED) WHEN ADMINISTERED TO IMMUNOCOMPROMISED PARTICIPANTS ≥10 YEARS OF AGE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the safety, tolerability, and immunogenicity of 2 doses&#xD;
      of Trumenba® (on a 0- and 6-month schedule) in immunocompromised participants by functionally&#xD;
      assessing antibody production in asplenic and complement-deficient individuals ≥10 years of&#xD;
      age.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 18, 2021</start_date>
  <completion_date type="Anticipated">June 3, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 3, 2024</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1. The percentage of participants with serum bactericidal assay using human complement (hSBA) titer ≥ lower limit of quantitation (LLOQ) for each of the 4 primary Neisseria meningitidis serogroup B (MnB) test strains.</measure>
    <time_frame>1 month after Vaccination 2 in immunocompromised participants compared to historical age-matched healthy participants separately</time_frame>
    <description>Describe the immune response induced by 2 doses of Trumenba in immunocompromised participants and historical age-matched healthy participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>2. Percentage of participants reporting local reactions within 7 days after each vaccination.</measure>
    <time_frame>Within 7 days after each vaccination.</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>3. Percentage of participants reporting systemic events within 7 days after each vaccination.</measure>
    <time_frame>Within 7 days after each vaccination.</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>4. Percentage of participants reporting use of antipyretic medication within 7 days after each vaccination.</measure>
    <time_frame>Within 7 days after each vaccination.</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>5. Percentage of participants with at least 1 adverse event (AE) occurring 30 Days after each vaccination.</measure>
    <time_frame>Within 30 Days after each vaccination</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>6. Percentage of participants with at least 1 AE occurring 30 Days after any vaccination.</measure>
    <time_frame>Within 30 Days after any vaccination</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>7. Percentage of participants with at least 1 AE occurring during the vaccination phase.</measure>
    <time_frame>During the vaccination phase (from Vaccination 1 through 1 month after Vaccination 2)</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>8. Percentage of participants with at least 1 immediate AE after each vaccination.</measure>
    <time_frame>Throughout the study (from the time of vaccination administration until 30 minutes post vaccine administration)</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>9. Percentage of participants with at least 1 serious AE (SAE) within 30 Days after each vaccination.</measure>
    <time_frame>Within 30 Days after each vaccination</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>10. Percentage of participants with at least 1 SAE within 30 Days after any vaccination.</measure>
    <time_frame>Within 30 Days after any vaccination</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>11. Percentage of participants with at least 1 SAE during the vaccination phase.</measure>
    <time_frame>During the vaccination phase (from Vaccination 1 through 1 month after Vaccination 2)</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>12. Percentage of participants with at least 1 SAE during the follow-up phase.</measure>
    <time_frame>During the follow-up phase (from 1 month after Vaccination 2 through 6 months after Vaccination 2)</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>13. Percentage of participants with at least 1 SAE throughout the study.</measure>
    <time_frame>Throughout the study (from Vaccination 1 through 6 months after Vaccination 2)</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>14. Percentage of participants with at least 1 medically attended AE (MAE) within 30 Days after each vaccination.</measure>
    <time_frame>Within 30 Days after each vaccination</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>15. Percentage of participants with at least 1 MAE within 30 Days after any vaccination.</measure>
    <time_frame>Within 30 Days after any vaccination.</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>16. Percentage of participants with at least 1 MAE during the vaccination phase.</measure>
    <time_frame>During the vaccination phase (from Vaccination 1 through 1 month after Vaccination 2)</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>17. Percentage of participants with at least 1 MAE during the follow-up phase.</measure>
    <time_frame>During the follow-up phase (from 1 month after Vaccination 2 through 6 months after Vaccination 2)</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>18. Percentage of participants with at least 1 MAE throughout the study.</measure>
    <time_frame>Throughout the study (from Vaccination 1 through 6 months after Vaccination 2)</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>19. Percentage of participants with at least 1 newly diagnosed chronic medical condition (NDCMC) during the vaccination phase.</measure>
    <time_frame>During the vaccination phase (from Vaccination 1 through 1 month after Vaccination 2)</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>20. Percentage of participants with at least 1 NDCMC during the follow-up phase.</measure>
    <time_frame>During the follow-up phase (from 1 month after Vaccination 2 through 6 months after Vaccination 2)</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>21. Percentage of participants with at least 1 NDCMC throughout the study.</measure>
    <time_frame>Throughout the study (from Vaccination 1 through 6 months after Vaccination 2)</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>22. Number of days participants missed school or work because of AEs during the vaccination phase</measure>
    <time_frame>During the vaccination phase (from Vaccination 1 through 1 month after Vaccination 2)</time_frame>
    <description>Evaluate the safety profile of Trumenba in immunocompromised participants and historical age matched healthy participants.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Meningococcal Vaccine</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bivalent recombinant lipoprotein 2086 vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trumenba</intervention_name>
    <description>Bivalent recombinant lipoprotein 2086 vaccine</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participants ≥10 years of age at the time of consent.&#xD;
&#xD;
          -  Participants with an increased risk for meningococcal disease due to anatomic asplenia&#xD;
             or functional asplenia (eg, sickle cell anemia) or complement deficiencies.&#xD;
&#xD;
          -  Negative urine pregnancy test for all female participants.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous vaccination with any meningococcal serogroup B vaccine.&#xD;
&#xD;
          -  Participants who are receiving any allergen immunotherapy with a nonlicensed product&#xD;
             or receiving allergen immunotherapy with a licensed product and are not on stable&#xD;
             maintenance doses.&#xD;
&#xD;
          -  History of microbiologically proven disease caused by N meningitidis or Neisseria&#xD;
             gonorrhoeae.&#xD;
&#xD;
          -  Significant neurological disorder or history of seizure (excluding simple febrile&#xD;
             seizure).&#xD;
&#xD;
          -  Any neuroinflammatory or autoimmune condition, including, but not limited to,&#xD;
             transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.&#xD;
&#xD;
          -  Any confirmed or suspected human immunodeficiency virus infection.&#xD;
&#xD;
          -  Other medical or psychiatric condition including recent (within the past year) or&#xD;
             active suicidal ideation/behavior or laboratory abnormality that may increase the risk&#xD;
             of study participation or, in the investigator's judgment, make the participant&#xD;
             inappropriate for the study.&#xD;
&#xD;
          -  Receipt of immunoglobulin infusion or injection during the 42 days preceding&#xD;
             enrollment.&#xD;
&#xD;
          -  Current chronic use of systemic antibiotics.&#xD;
&#xD;
          -  Previous receipt or current use of complement inhibitors (eg, eculizumab,&#xD;
             ravulizumab).&#xD;
&#xD;
          -  Participation in other studies involving investigational drug(s) within 28 days prior&#xD;
             to study entry and/or during study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Staten Island University Hospital - Northwell Health</name>
      <address>
        <city>Staten Island</city>
        <state>New York</state>
        <zip>10305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>IN-VIVO Sp. z o.o.</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-048</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.</name>
      <address>
        <city>Krakow</city>
        <zip>30-348</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>WIP Warsaw IBD Point Profesor Kierkus</name>
      <address>
        <city>Warszawa</city>
        <zip>00-728</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Acibadem Adana Hastanesi</name>
      <address>
        <city>Adana</city>
        <zip>01130</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hacettepe Universitesi Tip Fakultesi</name>
      <address>
        <city>Ankara</city>
        <zip>06230</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mersin Universitesi Tip Fakultesi Hastanesi</name>
      <address>
        <city>Mersin</city>
        <zip>33343</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Poland</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B1971060</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 14, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 20, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningococcal Vaccine</keyword>
  <keyword>Meningitis Vaccine</keyword>
  <keyword>Asplenia</keyword>
  <keyword>Sickle cell anemia</keyword>
  <keyword>Complement deficiencies</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
    <ipd_url>https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

